Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guodong Su

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cell Death Discovery|July 27, 2021
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseasesYi Yu, Yuan Yan, Fanglin Niu, et al.
Cancer Biology & Medicine|June 14, 2022
The advanced development of molecular targeted therapy for hepatocellular carcinomaTao Yan, Lingxiang Yu, Ning Zhang, et al.
Frontiers in Oncology|November 28, 2022
Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patientsTao Yan, Chenyang Huang, Jin Lei, et al.
Annals of Translational Medicine|February 23, 2023
A multi-center retrospective study on the efficacy and safety of regorafenib <i>vs.</i> regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinomaTao Yan, Chenyang Huang, Caiyun Peng, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cell Death Discovery|July 27, 2021
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseasesYi Yu, Yuan Yan, Fanglin Niu, et al.
Cancer Biology & Medicine|June 14, 2022
The advanced development of molecular targeted therapy for hepatocellular carcinomaTao Yan, Lingxiang Yu, Ning Zhang, et al.
Frontiers in Oncology|November 28, 2022
Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patientsTao Yan, Chenyang Huang, Jin Lei, et al.
Annals of Translational Medicine|February 23, 2023
A multi-center retrospective study on the efficacy and safety of regorafenib <i>vs.</i> regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinomaTao Yan, Chenyang Huang, Caiyun Peng, et al.
Pageof 2